Heydari S, Kashani L, Noruzinia M
It is very helpful
It involves an identified patient, a licensed prescriber, a clinical rationale, pharmacy accountability, and the possibility of follow-up and adverse-event evaluation
For those specifically interested in fat loss rather than muscle growth, AOD 9604 offers the relevant benefits without the problematic side effects of full-length growth hormone
The trade-off is more time off the peptide, but often better results during active cycles
It may also offer a target for diagnostic testing that helps clinicians predict health outcomes and relapse-free survival for patients with a specific cancer type. After the embargo lifts, the article can be viewed at: This study was supported by National Cancer Institute grant (R21 CA191263)